KR950013509A - 비동기화 장애의 치료에 유용한 멜라토닌 유도체 - Google Patents

비동기화 장애의 치료에 유용한 멜라토닌 유도체 Download PDF

Info

Publication number
KR950013509A
KR950013509A KR1019940029488A KR19940029488A KR950013509A KR 950013509 A KR950013509 A KR 950013509A KR 1019940029488 A KR1019940029488 A KR 1019940029488A KR 19940029488 A KR19940029488 A KR 19940029488A KR 950013509 A KR950013509 A KR 950013509A
Authority
KR
South Korea
Prior art keywords
ethyl
acetamide
methoxy
methyl
hydrogen
Prior art date
Application number
KR1019940029488A
Other languages
English (en)
Inventor
에드워드 플라우 마이클
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950013509A publication Critical patent/KR950013509A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 다양한 메탈로닌 유사체를 사용하여 비동기화 장애를 치료하는 방법에 관한 것이다. 또한 본 발명은 이러한 방법에 사용하기 적합한 약학적 제제에 관한 것이다.

Description

비동기화 장애의 치료에 유용한 멜라토닌 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 비동기화 장애를 치료하는 약제를 제조하기 위한 하기 일반식의 화합물의 용도:
    상기 식에서, R1은 수소, C1-C4알킬 또는 C1-C4알콕시이고; R2는 수소 또는 C1-C4알킬이고; R3은 수소, C1-C4알킬, 페틸 또는 치환된 피넬이고; R4는 수소, 할로아세틸, C1-C5알카노일, 벤조일, 또는 할로 또는 메틸에 의해 치환된 벤조일이며; R5와 R6은 각각 독립적으로 수소 또는 할로이고, R7은 수소 또는 C1-C4알킬이며; 단, R2가 수소인 경우에는 R5와 R6중 적어도 하나가 할로이다.
  2. 제1항에 있어서, N-[2-메틸-2-(5-메톡시-6-플루오로인돌-3-일)에틸]아세트아미드; N-[2-에틸-2-(5-메톡시-6-클로로인돌-3-일)에틸]아세트아미드; N-[2-메틸-2- (5-메톡시-6,7-디클로로인돌-3-일)에틸]아세트아미드; 또는 N-[2-메틸-2-(5-메톡시 -6-클로로인들-3-일)에틸]아세트아미드로부터 선택되는 화합물을 사용하는 용도.
  3. 제1항에 있어서, N-[2-메틸-2-(5-메톡시-6-클로로인돌-3-일)에틸]아세트아미드; (+)-N-[2-메틸-2-(5-메톡시-6-클로로인돌-3-일)에틸]아세트아미드; 또는 (-)- N[2-메틸-2-(5-메톡시-6-클로로인돌-3-일)에틸]아세트아미드를 사용하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940029488A 1993-11-18 1994-11-11 비동기화 장애의 치료에 유용한 멜라토닌 유도체 KR950013509A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/154,903 US6180657B1 (en) 1993-11-18 1993-11-18 Melatonin derivatives for use in treating desynchronization disorders
US08-154903 1993-11-18

Publications (1)

Publication Number Publication Date
KR950013509A true KR950013509A (ko) 1995-06-15

Family

ID=22553300

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940029488A KR950013509A (ko) 1993-11-18 1994-11-11 비동기화 장애의 치료에 유용한 멜라토닌 유도체

Country Status (21)

Country Link
US (1) US6180657B1 (ko)
EP (1) EP0656209B1 (ko)
JP (1) JPH07196504A (ko)
KR (1) KR950013509A (ko)
CN (1) CN1100533C (ko)
AT (1) ATE239470T1 (ko)
AU (1) AU7777694A (ko)
CA (1) CA2135710C (ko)
CZ (1) CZ288834B6 (ko)
DE (1) DE69432626T2 (ko)
DK (1) DK0656209T3 (ko)
ES (1) ES2197904T3 (ko)
HU (1) HUT72070A (ko)
IL (1) IL111579A (ko)
NO (1) NO307364B1 (ko)
NZ (1) NZ264893A (ko)
PT (1) PT656209E (ko)
RU (1) RU2160101C2 (ko)
SG (1) SG77569A1 (ko)
UA (1) UA35588C2 (ko)
ZA (1) ZA948928B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748627A3 (en) * 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
CA2551117A1 (en) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc. Substituted melatonin derivatives, process for their preparation, and methods of use
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
CA2724782A1 (en) * 2008-05-19 2009-11-26 Takeda Pharmaceutical Company Limited An anti-cancer cytotoxic monoclonal antibody
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20180100450A (ko) 2012-01-26 2018-09-10 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
MX2015007909A (es) 2012-12-18 2016-04-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
RU2533965C1 (ru) * 2013-07-04 2014-11-27 Государственное бюджетное учреждение здравоохранения "Самарский областной гериатрический центр" Способ нормализации циркадианных ритмов человека
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
RU2655813C1 (ru) * 2017-06-09 2018-05-29 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Средство коррекции и профилактики состояний, вызванных нарушением суточных ритмов

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087444A (en) 1976-09-08 1978-05-02 Eli Lilly And Company Amides as ovulation inhibitors
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US4614807A (en) 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
US4687763A (en) 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
WO1989001472A1 (en) 1987-08-17 1989-02-23 Nelson Research & Development Co. Melatonin analogues
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
ZA928011B (en) * 1991-10-18 1993-06-23 Alza Corp Transdermal administration of melatonin.
US5196435A (en) 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
DK0656209T3 (da) 2003-09-01
PT656209E (pt) 2003-09-30
NO307364B1 (no) 2000-03-27
CZ276494A3 (en) 1995-07-12
HU9403299D0 (en) 1995-01-30
IL111579A (en) 1999-10-28
NZ264893A (en) 1997-06-24
EP0656209A3 (en) 1995-10-11
DE69432626D1 (de) 2003-06-12
ATE239470T1 (de) 2003-05-15
CA2135710C (en) 2007-07-10
NO944340D0 (no) 1994-11-14
CZ288834B6 (cs) 2001-09-12
HUT72070A (en) 1996-03-28
RU94041028A (ru) 1996-09-20
IL111579A0 (en) 1995-01-24
CN1100533C (zh) 2003-02-05
CA2135710A1 (en) 1995-05-19
EP0656209B1 (en) 2003-05-07
SG77569A1 (en) 2001-01-16
AU7777694A (en) 1995-05-25
UA35588C2 (uk) 2001-04-16
JPH07196504A (ja) 1995-08-01
CN1107700A (zh) 1995-09-06
NO944340L (no) 1995-05-19
DE69432626T2 (de) 2004-04-08
RU2160101C2 (ru) 2000-12-10
US6180657B1 (en) 2001-01-30
ES2197904T3 (es) 2004-01-16
EP0656209A2 (en) 1995-06-07
ZA948928B (en) 1996-05-10

Similar Documents

Publication Publication Date Title
KR940005270A (ko) 뼈 손실 예방에 유용한 벤조티오펜
ES2119984T3 (es) Nuevos compuestos propinil bi-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
KR920019342A (ko) 골질환 치료제
TR199800019T1 (xx) Trombosit topaklanmas�n� �nleyici yeni maddeler.
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
KR920018029A (ko) 신규한 카복실산 아미드
KR950013509A (ko) 비동기화 장애의 치료에 유용한 멜라토닌 유도체
KR950010893A (ko) 자궁내막증 억제 방법
KR900003151A (ko) 화합물
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
KR950013508A (ko) 수면 장애의 치료에 유용한 멜라토닌 유도체
KR950010892A (ko) 자궁 섬유증 억제 방법
NO902800L (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
DE69210410D1 (de) Retinoid enthaltende dermatologische und/oder kosmetische zusammensetzungen
PT90938A (pt) Processo para a preparacao de novas sulfonamidas e de composicoes farmaceuticas que as contem
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
DE69024778D1 (de) 2-Aminopyrimidin-4-carboxamid-Derivate, deren Herstellung und deren therapeutische Anwendung
DE69424009T2 (de) Verwendung von (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidinacetamid zur Herstellung eines Medikaments zur Behandlung von Angst
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR970074763A (ko) 불소화된 비타민 d₃ 유사체
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
KR930017885A (ko) 항종양 조성물 및 종양의 치료방법
GR3007400T3 (ko)

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B90T Transfer of trial file for re-examination
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040225

Effective date: 20050531

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050704

Effective date: 20060907